Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial

This Phase III study (n=246) found no overall survival benefit associated with use of preoperative chemoradiotherapy in the treatment of borderline resectable pancreatic cancer (median 16.0 months versus 14.3 months with immediate surgery; HR 0.78; 95% CI 0.58 to 1.05; P=0.096).


Journal of Clinical Oncology